⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,4-Butanediol SCHEMBL2537863 | 0.89 | — | — | |
| 1,3-Propanediol SCHEMBL32660964 | 0.80 | — | — | |
| Ethylene Glycol SCHEMBL2307225 | 0.76 | — | — | |
| Butyl Alcohol SCHEMBL19899953 | 0.74 | — | — | |
| SCHEMBL1330915 | 0.74 | — | — | |
| 1,4-Butanediol SCHEMBL14477517 | 0.74 | — | — | |
| Butyl Alcohol SCHEMBL19899826 | 0.74 | — | — | |
| 3-Chloropropanol SCHEMBL13750816 | 0.74 | — | — | |
| 1,4-Butanediol SCHEMBL31172891 | 0.74 | — | — | |
| SCHEMBL14477544 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617768-B2 | Radiolabeled cannabinoid receptor 2 ligand | HOFFMANN-LA ROCHE INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-3813888-B1 | RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-20250179026-A1 | Deuterium-Enriched 3,5-Dimethylpyrazolyl-3-propoxy-4-fluorobenzoic Acids for Treatment of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) and Polyneuropathy (ATTR-PN), and Related Diseases | DHANOA DALJIT SINGH (US) | 2025-06-05 | — | — | US | disclosed |
| EP-3814337-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| US-20240308974-A1 | RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND | HOFFMANN LA ROCHE (US) | 2024-09-19 | — | — | US | disclosed |
| EP-3577118-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4422750-A1 | LRRK2 INHIBITORS | H. Lundbeck A/S (DK) | 2024-09-04 | — | — | EP | disclosed |
| CN-118251397-A | LRRK2 inhibitors | H.隆德贝克有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11999710-B2 | Radiolabeled cannabinoid receptor 2 ligand | HOFFMANN-LA ROCHE INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-2897948-B1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2016-08-31 | — | — | EP | disclosed |
| US-20160128996-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| US-20160128996-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| US-9266857-B2 | Bicyclic AZA compounds as muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-9266857-B2 | Bicyclic AZA compounds as muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| EP-2897948-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014045031-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-03-27 | — | — | WO | disclosed |
| US-20100076010-A1 | ALPHA 1A-ADRENOCEPTOR ANTAGONISTS | CONCERT PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |